Knte stock – Kinnate Biopharma Inc. Stock Company Profile
KNTE Stock – Kinnate Biopharma Inc.
Kinnate Biopharma Inc., as a biopharmaceutical firm, specializes in discovering and advancing small molecule kinase inhibitors for treating cancers defined by genomics in the U.S. The Company developed KIN-2787, a fast-track fibrosarcoma inhibitor for patients with lung cancer, melanoma, and various solid tumors; KIN-3248, a small molecule kinase inhibitor targeting changes in fibroblast growth factor receptor FGFR2 and FGFR3 genes; and small molecule research programs encompassing CDK12. In 2018, the Company was formed and was headquartered in San Francisco, California. Formerly, Kinnate Biopharma Inc. operated as a Fount Therapeutics, LLC division.
Information
Address: 103 Montgomery Street, Suite 150, The Presidio of San Francisco, San Francisco, CA 94129
Contact number: 858 299 4699
Website: www.kinnate.com
Industry: Biotechnology
Sector: Healthcare
About Kinnate Biopharma Inc.
Kinnate Biopharma Inc. is a company in the clinical stage of precision oncology founded on the mission to bring hope to people living with cancer by refining the prospects of targeted therapies. The Company focuses on resolving known oncogenic drivers for which no presently approved targeted therapies exist. It also seeks to tackle issues related to existing cancer therapies, including a lack of responsiveness and the emergence of either acquired or intrinsic resistance.
Exarafenib, an under-investigation pan-RAF inhibitor targeting cancers with BRAF or NRAS-driven mutations, stood as one of the Company’s primary product candidates. The other lead product candidate from the Company is KIN-3248, an investigational FGFR inhibitor for those cancers with FGFR2 or FGFR3 alterations.
The Company operated early-stage efforts consisting of a c-MET inhibitor aimed at resistant variants and a brain-penetrant CDK4 selective program. Investors researching other speculative biotechnology and technology stocks can also compare KNTE with MLGO stock to understand the differences between clinical-stage biotechnology companies and small-cap technology businesses.
To learn more about the company’s historical research and development activities, investors should consult authoritative regulatory and corporate sources.
Kinnate Biopharma Inc. Performance
Financial Results
Winding down September 30, 2023, with $180.3 million in cash, cash equivalents, and investments, Kinnate Biopharma was searching for financing that would sustain operations until at least the second quarter of 2026. The net loss for the third quarter of 2023 was $30.7 million for the Company.
The financial position reflected the challenges faced by a clinical-stage biotechnology company, where significant research and development expenses can occur before commercial products generate revenue.
For investors evaluating other small-cap companies, APLD stock offers another example of how market participants can assess companies with different business models, growth expectations, and risk profiles.
Exarafenib and Binimetinib
In a study of patients with NRAS mutant melanoma, the combination of exarafenib and binimetinib showed a 38% overall response rate and a 69% disease control rate.
These results were relevant to Kinnate’s research strategy because the company was focused on developing targeted therapies for cancers driven by specific genomic alterations.
KIN-3248
Kinnate Biopharma’s KIN-3248 is a small-molecule kinase inhibitor that targets FGFR2 and FGFR3 genes commonly associated with solid tumor cancers. The Company conducted a multi-center, open-label clinical trial to assess the safety, acceptability, and efficacy of KIN-3248.
The development of targeted therapies such as KIN-3248 represented Kinnate’s broader focus on precision oncology and therapies designed around specific molecular characteristics of cancer.
Strategic Review
In September 2023, Kinnate Biopharma announced plans to lay off about 70% of its workforce and suspend the development of three assets.
This strategic review demonstrated the financial and operational challenges associated with advancing multiple clinical-stage drug candidates simultaneously. For investors, such restructuring decisions can be important when evaluating the future prospects and risk profile of a biotechnology company.
Acquisition
In February 2024, Kinnate Biopharma agreed to be acquired by XOMA Corporation.
The acquisition marked an important development in Kinnate’s corporate history and significantly changed the company’s independent operating structure.
KNTE Financial Forecast
KNTE Earnings Forecast
Next quarter’s earnings estimate for KNTE is -$0.29, with a range of -$0.29 to -$0.29. The previous quarter’s EPS was -$0.36. KNTE beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS assessment 57.50% in the same period. In the last calendar year, KNTE has outperformed its overall sector.
However, historical earnings estimates should be interpreted carefully because corporate events, acquisitions, restructuring, and changes in a company’s operating status can affect how financial data is reported.
KNTE Sales Forecast
Next quarter’s sales forecast for KNTE is $0.00, with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. KNTE beat its sales estimates 0.00% of the time in the past 12 months, while its overall industry beat sales estimates 47.36% in the same period. In the last calendar year, KNTE has underperformed its overall sector.
The absence of meaningful sales is not unusual for a clinical-stage biotechnology company whose primary activities center on research and development rather than commercial product sales.
KNTE Stock Outlook
Kinnate Biopharma’s history illustrates the high-risk nature of clinical-stage biotechnology companies. Drug-development programs can offer substantial potential when clinical results are successful, but they can also face setbacks from clinical results, regulatory decisions, funding requirements, competition, or strategic changes.
The company’s acquisition by XOMA also means investors should distinguish historical KNTE information from the company’s post-acquisition corporate structure. Historical stock data and financial forecasts may therefore require additional context before being used for current investment decisions.
Investors comparing different speculative equities may also review BRSH stock to explore another small-cap company and understand how company-specific developments can influence investor sentiment.
Conclusion
Kinnate Biopharma Inc. was a clinical-stage biotechnology company focused on precision oncology and the development of targeted small-molecule kinase inhibitors. Its research programs included exarafenib and KIN-3248, with the company seeking to address cancers associated with specific genomic alterations.
However, financial pressures, workforce reductions, suspended development programs, and the eventual acquisition by XOMA Corporation significantly changed Kinnate’s corporate trajectory.
For anyone researching KNTE stock, it is important to consider both the company’s historical clinical-development story and the implications of its acquisition. Historical forecasts and stock information should not be treated as current investment guidance without checking the latest corporate and regulatory information.
As with any speculative investment, investors should conduct independent research, review official filings, and consider the risks before making financial decisions.